DGIdb - MET Gene Record

MET 4233 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

4233
MET PROTO-ONCOGENE, RECEPTOR TYROSINE KINASE
MET
AUTS9
DFNB97
HGFR
RCCP2
c-Met
164860
7029
ENSG00000105976
OTTHUMG00000023299
MET_HUMAN
P08581
HEPATOCYTE GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (MET PROTO- ONCOGENE TYROSINE KINASE) (C-MET) (HGF RECEPTOR) (HGF-SF RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P08581]
HEPATOCYTE GROWTH FACTOR RECEPTOR
PA30763
SF receptor
HGF receptor
Tyrosine-protein kinase Met
Scatter factor receptor
Proto-oncogene c-Met
HGF/SF receptor
52
T40474

Gene Info:

Initial Gene Query	MET
Counted Citations from 1950-2000	4560
Human Readable Name	DRUGGABLE GENOME
Human Readable Name	KINASE
Interpro Type	Domain
Uniprot Evidence	1: Evidence at protein level
Uniprot Status	Swiss-Prot
Interpro Acc	IPR001245
Interpro Short Name	Ser-Thr/Tyr_kinase_cat_dom
Interpro Name	Serine-threonine/tyrosine-protein kinase catalytic domain
CancerCommons Reported Gene Name	MET
CancerCommons Reported Gene Name	MET, VEGFRs, Axl, Tie2, Ron
Target Class	Receptors
Target Subclass	EC:2.7.10.1
Gene Biotype	PROTEIN_CODING

(28 More Sources)

Gene Categories: Category Details

CELL SURFACE
KINASE
TYROSINE KINASE
DRUG RESISTANCE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE

Publications:

Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
Patnaik et al., 2014, Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma., Br. J. Cancer
Phillip et al., 2013, Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines., J Hematol Oncol
Lorenzato et al., 2002, Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion., Cancer Res.
Maulik et al., 2002, Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition., Cytokine Growth Factor Rev.
Bardelli et al., 1998, Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth., Proc. Natl. Acad. Sci. U.S.A.
MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
Olivero et al., 1999, Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family., Int. J. Cancer
Dalinka et al., 1975, The radiology of osseous and articular infection., CRC Crit Rev Clin Radiol Nucl Med
Zou et al., 2007, An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms., Cancer Res.
Forde et al., 2012, Crizotinib in the treatment of non-small-cell lung cancer., Expert Opin Pharmacother
Chu LP et al., 2019, MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel <i>MET</i> R1004G Mutation., Oncologist
Frampton et al., 2015, Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors., Cancer Discov
Awad et al., 2016, MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression., J. Clin. Oncol.
Paik et al., 2015, Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping., Cancer Discov
Togashi et al., 2015, MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor., Lung Cancer
Bardelli et al., 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer., Cancer Discov
Palma et al., 2014, Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary., Case Rep Oncol
Le et al., 2015, Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling., Clin Lung Cancer
Pietrantonio et al., 2016, MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer., Cancer Discov
Tanizaki et al., 2011, MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations., J Thorac Oncol
Chi et al., 2012, Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor., J. Clin. Oncol.
Ou et al., 2011, Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification., J Thorac Oncol
Ou SH, 2011, Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond., Drug Des Devel Ther
Li et al., 2017, Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer., Clin. Cancer Res.
Choi et al., 2004, Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein., Cancer Cell Int.
Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
Qi et al., 2011, Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors., Cancer Res.
Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
Shen et al., 2015, c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers., Cancer Res.
Ou et al., 2016, High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression., Lung Cancer
Pfefferle et al., 2016, Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers., Dis Model Mech
Chabon et al., 2016, Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients., Nat Commun
Secrier et al., 2016, Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance., Nat. Genet.
Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov
Heist et al., 2016, Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping., J Thorac Oncol
Engstrom et al., 2017, Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models., Clin. Cancer Res.
Lu et al., 2017, MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma., Cancer Res.
Moro-Sibilot D et al., 2019, Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial., Ann Oncol
Landi L et al., 2019, Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial., Clin Cancer Res
Mahjoubi L et al., 2016, A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib., Invest New Drugs
Drilon A et al., 2020, Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration., Nat Med
Wiesweg M et al., 2020, Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation., Lung Cancer
Zhu YC et al., 2018, Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing., Ann Oncol
Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
Choueiri et al., 2017, Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer., J. Clin. Oncol.
Schuller et al., 2015, The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models., Clin. Cancer Res.
Lee J et al., 2019, Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial., Cancer Discov
Shah et al., 2017, Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial., JAMA Oncol
Spigel et al., 2013, Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer., J. Clin. Oncol.
Merchant et al., 2013, Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent., Proc. Natl. Acad. Sci. U.S.A.
Catenacci et al., 2011, Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence., Cancer Discov
Cheng et al., 2015, Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma., Cancer Res.
Qu et al., 2014, Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models., J. Exp. Clin. Cancer Res.
Falchook et al., 2015, Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors., Invest New Drugs
Busnena BA et al., 2013, Olive secoiridoids and semisynthetic bioisostere analogues for the control of metastatic breast cancer., Bioorg Med Chem
Dorsch D et al., 2015, Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors., Bioorg Med Chem Lett
Paik PK et al., 2020, Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations., N Engl J Med
Medová M et al., 2013, The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants., Mol Cancer Ther
Choueiri et al., 2013, Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma., J. Clin. Oncol.
Hudkins RL et al., 2012, Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent., J Med Chem
Nakagawa et al., 2010, E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models., Cancer Sci.
Minuti et al., 2012, Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer., Br. J. Cancer
Rosen et al., 2017, A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer., Clin. Cancer Res.
Wang et al., 2017, ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence., Clin. Cancer Res.
Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
Wolf J et al., 2020, Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung Cancer., N Engl J Med
Hong JY et al., 2011, Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa., J Nat Prod
Fujita et al., 2013, The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile., Mol. Cancer Ther.
Egile et al., 2015, The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer., Mol. Cancer Ther.
Yamaoka et al., 2016, Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation., Mol. Cancer Ther.
Shien et al., 2013, Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells., Cancer Res.
Rho et al., 2014, MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation., Cancer Res.
Engelman et al., 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling., Science
Zhang D et al., 2013, Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors., Bioorg Med Chem
Smith et al., 2015, Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2., Mol. Cancer Ther.
Piao et al., 2016, Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models., Neuro-oncology
Kwon et al., 2015, Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment., Oncogene
McDermott U et al., 2007, Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling., Proc Natl Acad Sci U S A
Ortiz-Cuaran et al., 2016, Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors., Clin. Cancer Res.
Ninomiya K et al., 2018, MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib., Sci Rep
Dai et al., 2012, Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation., Clin. Exp. Metastasis
Dai et al., 2010, BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro., Mol. Cancer Ther.
Hugo et al., 2015, Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance., Cell
Dabir et al., 2014, RET mutation and expression in small-cell lung cancer., J Thorac Oncol
Hong DS et al., 2015, A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors., Oncotarget
Sameni et al., 2016, Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models., Clin. Cancer Res.
Goyal et al., 2017, A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma., Cancer
Yakes et al., 2011, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth., Mol. Cancer Ther.
Kurzrock et al., 2011, Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer., J. Clin. Oncol.
Nakatani M et al., 2017, The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma <i>In Vitro</i> and <i>In Vivo</i>., Anticancer Res
Moores et al., 2016, A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors., Cancer Res.
Yang SP et al., 2012, Potent HGF/c-Met axis inhibitors from Eucalyptus globulus: the coupling of phloroglucinol and sesquiterpenoid is essential for the activity., J Med Chem
Foster et al., 2015, The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models., Mol. Cancer Ther.
Liu et al., 2014, LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth., Clin. Cancer Res.
Larsen CA et al., 2009, Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies., J Med Chem
Arena S et al., 2007, Genetic targeting of the kinase activity of the Met receptor in cancer cells., Proc Natl Acad Sci U S A
Wittman MD et al., 2009, Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development., J Med Chem

TEPOTINIB MET

Interaction Score: 4.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
25736998 32469185 24061647

Sources:
DTC ChemblInteractions CIViC TTD
TIVANTINIB MET

Interaction Score: 3.53

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Reported Cancer Type Lung, Prostate

Trial Name ARQ-197

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions CancerCommons TTD
ONARTUZUMAB MET

Interaction Score: 3.24

Interaction Types & Directionality:

antibody (inhibitory)

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type esophagus adenocarcinoma

Indication/Tumor Type gastroesophageal junction adenocarcinoma

Response Type no benefit

PMIDs:
27918764 24101053 23882082 22389872

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC CancerCommons
SAVOLITINIB MET

Interaction Score: 2.94

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
28396313 28644771 25779944 27694386 31315834

Sources:
JAX-CKB ChemblInteractions COSMIC CIViC TTD
EMIBETUZUMAB MET

Interaction Score: 2.36

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Approval Status Preclinical

Indication/Tumor Type non-small cell lung carcinoma

combination therapy Emibetuzumab + Erlotinib

PMIDs:
25231402 27803065

Sources:
JAX-CKB TTD
CAPMATINIB MET

Interaction Score: 2.36

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Indication/Tumor Type lung large cell carcinoma

Response Type sensitive

PMIDs:
28396313 15494073 28783719 27694386 28765324 25971938 32877583

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions COSMIC CIViC CancerCommons TTD OncoKB
BMS-777607 MET

Interaction Score: 2.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
28396313 22286523 20515943

Sources:
MyCancerGenome JAX-CKB ChemblInteractions TTD
CRIZOTINIB MET

Interaction Score: 1.83

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Clinical Status preclinical

Pathway activation

Variant Effect gain-of-function

PMIDs:
12460923 11750879 9826708 25157968 10417759 1104268 17483355 22594847 31391294 25971938 26729443 25971939 26547802 23729478 25232318 25922291 27325282 21716144 22162573 21623265 22162641 28396313 28514312 15494073 26779812 21266357 26432108 26483207 27393507 27149990 27283993 27595477 27694386 27343442 28765324 28522754 31584608 31416808 26892698 31932802 31809977 30339198 10592235

Sources:
TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions DoCM COSMIC CIViC MyCancerGenomeClinicalTrial PharmGKB TTD OncoKB
TELISOTUZUMAB MET

Interaction Score: 1.77

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Phase I

PMIDs:
None found

Sources:
JAX-CKB ChemblInteractions TTD
TELISOTUZUMAB VEDOTIN MET

Interaction Score: 1.77

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

Approval Status Phase I

PMIDs:
27573171

Sources:
JAX-CKB TTD
EUCALYPTIN A MET

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22934600

Sources:
DTC
MACROCARPAL B MET

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22934600

Sources:
DTC
GALLOCATECHIN GALLATE MET

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19839593

Sources:
DTC
MACROCARPAL A MET

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22934600

Sources:
DTC
EMD-1204831 MET

Interaction Score: 1.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
AMG-208 MET

Interaction Score: 1.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
26155941

Sources:
ChemblInteractions
(-)-OLEOCANTHAL MET

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23403296

Sources:
DTC
PF-04217903 MET

Interaction Score: 1.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC DTC MyCancerGenome ChemblInteractions COSMIC TTD
JNJ-38877605 MET

Interaction Score: 1.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
SAR-125844 MET

Interaction Score: 1.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Indication/Tumor Type lung cancer

PMIDs:
25504634

Sources:
JAX-CKB ChemblInteractions TTD
TYROSOL SINAPATE MET

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23403296

Sources:
DTC
CHEMBL261641 MET

Interaction Score: 0.88

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23403296 17595299

Sources:
DTC
TAS-115 MET

Interaction Score: 0.88

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

Indication/Tumor Type stomach cancer

PMIDs:
24140932

Sources:
JAX-CKB ChemblInteractions
OSIMERTINIB MET

Interaction Score: 0.82

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical

Response Type resistant

Evidence Type Actionable

PMIDs:
27252416 27393507 27694386 29386539

Sources:
JAX-CKB CIViC OncoKB
GOLVATINIB MET

Interaction Score: 0.79

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

Indication/Tumor Type stomach cancer

PMIDs:
19832844

Sources:
JAX-CKB ChemblInteractions TTD
CABOZANTINIB MET

Interaction Score: 0.72

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

PMIDs:
28396313 27694386 26432786 28192597 25971939 21926191 21606412 29061793

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB CIViC MyCancerGenomeClinicalTrial TTD OncoKB
PHA-665752 MET

Interaction Score: 0.71

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy Gefitinib + PHA-665752

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
18077425 21266357 23542356 24165158

Sources:
DTC JAX-CKB
NAQUOTINIB MET

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29386539

Sources:
CIViC
MK-8033 MET

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
COMETRIQ MET

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

PMIDs:
None found

Sources:
CancerCommons
JNJ-61186372 MET

Interaction Score: 0.59

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
27216193

Sources:
JAX-CKB
APRATOXIN F MET

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
BMS-698769 MET

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
GLESATINIB MET

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Reported Cancer Type Lung

Trial Name MGCD265

PMIDs:
15494073 27694386 28765324

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB CancerCommons
MERESTINIB MET

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
AMG-337 MET

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
SGX-523 MET

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
FICLATUZUMAB MET

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type multiple myeloma

Response Type predicted – sensitive

Approval Status Phase I

PMIDs:
24901237

Sources:
JAX-CKB
AMUVATINIB MET

Interaction Score: 0.5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

Trial Name MP-470

PMIDs:
24326130

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions
FORETINIB MET

Interaction Score: 0.49

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Approval Status Preclinical

combination therapy Foretinib + Rucaparib

Evidence Type Actionable

PMIDs:
26779812 23213094

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC CancerCommons TTD
ALTIRATINIB MET

Interaction Score: 0.44

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Approval Status Preclinical

PMIDs:
26285778 26965451 24362531

Sources:
JAX-CKB ChemblInteractions TTD
EPICATECHIN GALLATE MET

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19839593

Sources:
DTC
BPI-9016 MET

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ALVESPIMYCIN MET

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type predicted – sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
26483207

Sources:
JAX-CKB
LY-3164530 MET

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CMX-2043 MET

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
SITRAVATINIB MET

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
CABOZANTINIB S-MALATE MET

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
BMS-794833 MET

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
BMS-817378 MET

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
YUANHUADINE MET

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21916433

Sources:
DTC
ARRY-300 MET

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
MK-2461 MET

Interaction Score: 0.15

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions TTD
GANETESPIB MET

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type predicted – sensitive

Approval Status Preclinical - Cell culture

PMIDs:
26483207

Sources:
JAX-CKB
CHEMBL399530 MET

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AFATINIB MET

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

Approval Status Clinical Study

PMIDs:
27694386

Sources:
JAX-CKB
VELIPARIB MET

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
26779812

Sources:
JAX-CKB
CEP-11981 MET

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22148921

Sources:
DTC
MGCD-265 MET

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CRENOLANIB MET

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial
BMS-754807 MET

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19778024

Sources:
DTC
TRASTUZUMAB MET

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type sensitive

combination therapy Crizotinib + Trastuzumab + Paclitaxel

combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin

PMIDs:
26432108 22850551

Sources:
JAX-CKB
GEFITINIB MET

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical - Cell culture

combination therapy Gefitinib + NPS-1034

Approval Status Preclinical - Cell line xenograft

PMIDs:
27612490 23542356 24165158 17463250 23993328

Sources:
DTC JAX-CKB CIViC OncoKB
BEVACIZUMAB MET

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Altiratinib + Bevacizumab

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
25363205 26432108 26965451

Sources:
JAX-CKB
ERLOTINIB MET

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Onartuzumab + Erlotinib

Indication/Tumor Type non-small cell lung carcinoma

Response Type conflicting

PMIDs:
27694386 27803065 24101053

Sources:
DTC JAX-CKB OncoKB
SELUMETINIB MET

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Selumetinib + BEZ235

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
25952648 24939055

Sources:
JAX-CKB CIViC
LAPATINIB MET

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Crizotinib + Lapatinib

Indication/Tumor Type esophagus adenocarcinoma

Response Type sensitive

PMIDs:
26432108 27595477

Sources:
JAX-CKB
VEMURAFENIB MET

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26359985 27325282

Sources:
CIViC
PILARALISIB MET

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
25637314

Sources:
JAX-CKB
TRAMETINIB MET

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy INC280 + Trametinib

Indication/Tumor Type collecting duct carcinoma

Response Type sensitive

PMIDs:
28783719 25952648

Sources:
JAX-CKB CIViC
PANITUMUMAB MET

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy JNJ 38877605 + Panitumumab

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
23729478

Sources:
JAX-CKB
PONATINIB MET

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung small cell carcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
25122427

Sources:
JAX-CKB
EPIGALOCATECHIN GALLATE MET

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19839593

Sources:
DTC
OLAPARIB MET

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
26779812

Sources:
JAX-CKB
LEUCOVORIN MET

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin

Indication/Tumor Type gastric adenocarcinoma

Response Type resistant

PMIDs:
26432108

Sources:
JAX-CKB
CETUXIMAB MET

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type sensitive

combination therapy Cetuximab + JNJ 38877605

Approval Status Preclinical - Cell culture

PMIDs:
23729478

Sources:
JAX-CKB CIViC
DACTOLISIB MET

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
24939055

Sources:
DTC JAX-CKB
RUCAPARIB MET

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

combination therapy Foretinib + Rucaparib

Approval Status Preclinical - Cell line xenograft

PMIDs:
26779812

Sources:
JAX-CKB
CHEMBL202721 MET

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAPECITABINE MET

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type resistant

Evidence Type Actionable

Approval Status Clinical Study

PMIDs:
26432108

Sources:
JAX-CKB
OXALIPLATIN MET

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab

Indication/Tumor Type gastric adenocarcinoma

Response Type resistant

PMIDs:
26432108

Sources:
JAX-CKB
IMATINIB MET

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Imatinib + Carboplatin + Paclitaxel

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
28514312

Sources:
JAX-CKB
CHEMBL546797 MET

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PACLITAXEL MET

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type gastric adenocarcinoma

combination therapy Crizotinib + Trastuzumab + Paclitaxel

Evidence Type Actionable

PMIDs:
26432108 28514312

Sources:
JAX-CKB
DASATINIB MET

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type predicted – sensitive

Approval Status Preclinical - Cell culture

PMIDs:
26483207

Sources:
JAX-CKB
CHEMBL541400 MET

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CARBOPLATIN MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Imatinib + Carboplatin + Paclitaxel

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
28514312

Sources:
JAX-CKB
SORAFENIB MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Sorafenib

Indication/Tumor Type gastrointestinal stromal tumor

Response Type sensitive

PMIDs:
25363205

Sources:
JAX-CKB
PAZOPANIB MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1997335 MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SNS-314 MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OSI-632 MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
JNJ-7706621 MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PD-0166285 MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FLUOROURACIL MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin

Indication/Tumor Type gastric adenocarcinoma

Response Type resistant

PMIDs:
26432108

Sources:
JAX-CKB
ENTRECTINIB MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LINIFANIB MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
R-406 MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SP-600125 MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CYC-116 MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TAE-684 MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PF-00562271 MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ILORASERTIB MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CENISERTIB MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

Ensembl: ENSG00000105976
- Version: 101_38
Alternate Names:

MET Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: P08581
- Version: January-2014
Alternate Names:

MET Gene Symbol

Gene Info:

Target Class Receptors

Target Subclass EC:2.7.10.1

Publications:
CancerCommons: MET
- Version: 25-July-2013
Alternate Names:

4233 Entrez Gene ID

Gene Info:

CancerCommons Reported Gene Name MET

CancerCommons Reported Gene Name MET, VEGFRs, Axl, Tie2, Ron

Publications:
BaderLabGenes: MET
- Version: February-2014
Alternate Names:

4233 Entrez Gene ID

Gene Info:

Initial Gene Query MET

Counted Citations from 1950-2000 4560

Gene Categories:

KINASE

Publications:
HopkinsGroom: P08581
- Version: 11-September-2012
Alternate Names:

MET_HUMAN Uniprot Id

4233 Entrez Gene Id

P08581 Uniprot Accession

Gene Info:

Human Readable Name KINASE

Interpro Type Domain

Uniprot Evidence 1: Evidence at protein level

Gene Categories:

KINASE, DRUGGABLE GENOME

Publications:

RussLampel: ENSG00000105976

Version: 26-July-2011

Alternate Names:

ENSG00000105976 Ensembl Gene Id

MET Display Id

HEPATOCYTE GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (MET PROTO- ONCOGENE TYROSINE KINASE) (C-MET) (HGF RECEPTOR) (HGF-SF RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P08581] Description

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

JAX-CKB: MET

Version: 27-September-2017

Alternate Names:

4233 CKB Entrez Id

MET CKB Gene Synonym

AUTS9 CKB Gene Synonym

Gene Info:

Publications:

Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)

Bardelli et al., 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer., Cancer Discov

Engelman et al., 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling., Science

PharmGKB: MET

Version: 18-August-2020

Alternate Names:

PA30763 PharmGKB ID

Gene Info:

Publications:

Ou SH, 2011, Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond., Drug Des Devel Ther

CIViC: MET

Version: 14-September-2020

Alternate Names:

4233 Entrez Gene ID

52 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Bardelli et al., 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer., Cancer Discov

Lee J et al., 2019, Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial., Cancer Discov

Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov

DoCM: MET

Version: 27-September-2017

Alternate Names:

Gene Info:

Publications:

Lorenzato et al., 2002, Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion., Cancer Res.

Bardelli et al., 1998, Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth., Proc. Natl. Acad. Sci. U.S.A.

Dalinka et al., 1975, The radiology of osseous and articular infection., CRC Crit Rev Clin Radiol Nucl Med

DTC: MET

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

McDermott U et al., 2007, Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling., Proc Natl Acad Sci U S A

Yang SP et al., 2012, Potent HGF/c-Met axis inhibitors from Eucalyptus globulus: the coupling of phloroglucinol and sesquiterpenoid is essential for the activity., J Med Chem

Dorsch D et al., 2015, Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors., Bioorg Med Chem Lett

TALC: MET
- Version: 12-May-2016
Alternate Names:

MET Gene Symbol

Gene Info:

Publications:
TALC: HGFR
- Version: 12-May-2016
Alternate Names:

HGFR Gene Symbol

Gene Info:

Publications:
MyCancerGenome: MET
- Version: 20-Jun-2017
Alternate Names:

4233 Entrez Gene Id

MET MyCancerGenome Gene Symbol

MET MyCancerGenome Reported Gene Name

Gene Info:

Publications:
HingoraniCasas: ENSG00000105976
- Version: 31-May-2017
Alternate Names:

ENSG00000105976 Gene Symbol

MET Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
TALC: C-MET
- Version: 12-May-2016
Alternate Names:

C-MET Gene Symbol

Gene Info:

Publications:
ChemblInteractions: MET
- Version: chembl_23
Alternate Names:

MET GENE_SYMBOL

Hepatocyte growth factor receptor UNIPROT

HGF/SF receptor UNIPROT

Gene Info:

Publications:
OncoKB: MET
- Version: 23-July-2020
Alternate Names:

4233 OncoKB Entrez Id

RCCP2 OncoKB Gene Synonym

HGFR OncoKB Gene Synonym

Gene Info:

Publications:
Tempus: MET
- Version: 11-November-2018
Alternate Names:

MET Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
dGene: MET
- Version: 27-Jun-2013
Alternate Names:

4233 Gene ID

AUTS9 dGene Synonym

HGFR dGene Synonym

Gene Info:

Gene Categories:

KINASE, TYROSINE KINASE

Publications:
TTD: Proto-oncogene c-Met
- Version: 2020.06.01
Alternate Names:

MET TTD Gene Abbreviation

T40474 TTD Target ID

Gene Info:

Publications:
Pharos: MET
- Version: 01-February-2022
Alternate Names:

Hepatocyte growth factor receptor Gene Name

P08581 UniProt ID

Gene Info:

Gene Categories:

KINASE

Publications:
MyCancerGenomeClinicalTrial: MET
- Version: 30-February-2014
Alternate Names:

Gene Info:

Publications:
MskImpact: MET
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
ClearityFoundationBiomarkers: MET
- Version: 26-July-2013
Alternate Names:

Gene Info:

Publications:
ClearityFoundationClinicalTrial: MET
- Version: 15-June-2013
Alternate Names:

Gene Info:

Publications:
ClearityFoundationClinicalTrial: C-MET
- Version: 15-June-2013
Alternate Names:

Gene Info:

Publications:
FoundationOneGenes: MET
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: MET
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
GO: MET
- Version: 01-February-2022
Alternate Names:

Gene Info:

Gene Categories:

CELL SURFACE, TYROSINE KINASE

Publications:
Oncomine: MET
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
COSMIC: MET
- Version: 4-Sep-2020
Alternate Names:

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Mechanism of Interaction	Hepatocyte growth factor receptor inhibitor
Direct Interaction	yes

Indication/Tumor Type	esophagus adenocarcinoma
Indication/Tumor Type	gastroesophageal junction adenocarcinoma
Response Type	no benefit

Indication/Tumor Type	Advanced Solid Tumor
Response Type	resistant
Approval Status	Preclinical - Cell culture

Approval Status	Preclinical
Indication/Tumor Type	non-small cell lung carcinoma
combination therapy	Emibetuzumab + Erlotinib

Reported Cancer Type	Melanoma
Indication/Tumor Type	lung large cell carcinoma
Response Type	sensitive

Indication/Tumor Type	prostate cancer
Response Type	sensitive
Approval Status	Preclinical

Clinical Status	preclinical
Pathway	activation
Variant Effect	gain-of-function

Notes
Indication/Tumor Type	lung adenocarcinoma
Response Type	sensitive

combination therapy	Gefitinib + PHA-665752
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive

Indication/Tumor Type	multiple myeloma
Response Type	predicted – sensitive
Approval Status	Phase I

antibody (inhibitory)
antagonist (inhibitory)
inhibitor (inhibitory)

Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive
Approval Status	Preclinical

combination therapy	Altiratinib + Bevacizumab
Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive

combination therapy	Onartuzumab + Erlotinib
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	conflicting

combination therapy	Selumetinib + BEZ235
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive

combination therapy	Crizotinib + Lapatinib
Indication/Tumor Type	esophagus adenocarcinoma
Response Type	sensitive

combination therapy	INC280 + Trametinib
Indication/Tumor Type	collecting duct carcinoma
Response Type	sensitive

combination therapy	JNJ 38877605 + Panitumumab
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

Indication/Tumor Type	lung small cell carcinoma
Response Type	sensitive
Approval Status	Preclinical

combination therapy	Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
Indication/Tumor Type	gastric adenocarcinoma
Response Type	resistant

Indication/Tumor Type	breast cancer
combination therapy	Foretinib + Rucaparib
Approval Status	Preclinical - Cell line xenograft

MET Gene Record

MET 4233 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Hepatocyte growth factor receptor inhibitor Direct Interaction yes

PMIDs: 25736998 32469185 24061647

Sources: DTC ChemblInteractions CIViC TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Reported Cancer Type Lung, Prostate Trial Name ARQ-197

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions CancerCommons TTD

Interaction Types & Directionality: antibody (inhibitory) antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type esophagus adenocarcinoma Indication/Tumor Type gastroesophageal junction adenocarcinoma Response Type no benefit

PMIDs: 27918764 24101053 23882082 22389872

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC CancerCommons

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type resistant Approval Status Preclinical - Cell culture

PMIDs: 28396313 28644771 25779944 27694386 31315834

Sources: JAX-CKB ChemblInteractions COSMIC CIViC TTD

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info: Approval Status Preclinical Indication/Tumor Type non-small cell lung carcinoma combination therapy Emibetuzumab + Erlotinib

PMIDs: 25231402 27803065

Sources: JAX-CKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Reported Cancer Type Melanoma Indication/Tumor Type lung large cell carcinoma Response Type sensitive

PMIDs: 28396313 15494073 28783719 27694386 28765324 25971938 32877583

Sources: TALC MyCancerGenome JAX-CKB ChemblInteractions COSMIC CIViC CancerCommons TTD OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type prostate cancer Response Type sensitive Approval Status Preclinical

PMIDs: 28396313 22286523 20515943

Sources: MyCancerGenome JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Clinical Status preclinical Pathway activation Variant Effect gain-of-function

Sources: TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions DoCM COSMIC CIViC MyCancerGenomeClinicalTrial PharmGKB TTD OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Phase I

PMIDs: None found

Sources: JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type non-small cell lung carcinoma Response Type sensitive Approval Status Phase I

PMIDs: 27573171

Sources: JAX-CKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22934600

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22934600

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19839593

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22934600

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Hepatocyte growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Hepatocyte growth factor receptor inhibitor Direct Interaction yes

PMIDs: 26155941

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23403296

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Hepatocyte growth factor receptor inhibitor Direct Interaction yes Notes

PMIDs: None found

Sources: TALC DTC MyCancerGenome ChemblInteractions COSMIC TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Hepatocyte growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
25736998 32469185 24061647

Sources:
DTC ChemblInteractions CIViC TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Reported Cancer Type Lung, Prostate

Trial Name ARQ-197

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions CancerCommons TTD

Interaction Types & Directionality:

antibody (inhibitory)

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type esophagus adenocarcinoma

Indication/Tumor Type gastroesophageal junction adenocarcinoma

Response Type no benefit

PMIDs:
27918764 24101053 23882082 22389872

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC CancerCommons

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
28396313 28644771 25779944 27694386 31315834

Sources:
JAX-CKB ChemblInteractions COSMIC CIViC TTD

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Approval Status Preclinical

Indication/Tumor Type non-small cell lung carcinoma

combination therapy Emibetuzumab + Erlotinib

PMIDs:
25231402 27803065

Sources:
JAX-CKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Indication/Tumor Type lung large cell carcinoma

Response Type sensitive

PMIDs:
28396313 15494073 28783719 27694386 28765324 25971938 32877583

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions COSMIC CIViC CancerCommons TTD OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
28396313 22286523 20515943

Sources:
MyCancerGenome JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Clinical Status preclinical

Pathway activation

Variant Effect gain-of-function

Sources:
TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions DoCM COSMIC CIViC MyCancerGenomeClinicalTrial PharmGKB TTD OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Phase I

PMIDs:
None found

Sources:
JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

Approval Status Phase I

PMIDs:
27573171

Sources:
JAX-CKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
22934600

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22934600

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
19839593

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22934600

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
26155941

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
23403296

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC DTC MyCancerGenome ChemblInteractions COSMIC TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

Indication/Tumor Type lung cancer

PMIDs:
25504634

Sources:
JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
23403296

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23403296 17595299

Sources:
DTC

Response Type	resistant
Evidence Type	Actionable
Approval Status	Clinical Study

combination therapy	Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab
Indication/Tumor Type	gastric adenocarcinoma
Response Type	resistant

combination therapy	Imatinib + Carboplatin + Paclitaxel
Indication/Tumor Type	melanoma
Response Type	sensitive

combination therapy	Bevacizumab + Sorafenib
Indication/Tumor Type	gastrointestinal stromal tumor
Response Type	sensitive

MET_HUMAN	Uniprot Id
4233	Entrez Gene Id
P08581	Uniprot Accession

ENSG00000105976	Ensembl Gene Id
MET	Display Id
HEPATOCYTE GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (MET PROTO- ONCOGENE TYROSINE KINASE) (C-MET) (HGF RECEPTOR) (HGF-SF RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P08581]	Description

4233	Entrez Gene Id
MET	MyCancerGenome Gene Symbol
MET	MyCancerGenome Reported Gene Name

MET	GENE_SYMBOL
Hepatocyte growth factor receptor	UNIPROT
HGF/SF receptor	UNIPROT

4233	OncoKB Entrez Id
RCCP2	OncoKB Gene Synonym
HGFR	OncoKB Gene Synonym